Dr. Mackay received his PhD in molecular genetics from Carnegie-Mellon University. He completed three postdoctoral appointments from Harvard University School of Public Health (National Research Service Award No. CA 09078), Boston University, and North Carolina State University (National Research Service Award No. AG 05380), and served as Director of Quality at Xenometrix, Inc. Dr. Mackay is an Associate Professor in the Department of Biology & Health Services at Edinboro University teaching genetics, cell & molecular biology, and microbiology. He is a full member of the Society of Toxicology since 1995, and is the Treasuerer of the Allegheny-Erie Society of Toxicology since 2003. He has published more than 20 papers in reputed journals in the areas of cancer biology, genetics, and aging.
Megan Hitchins is an Associate Professor of Medicine (Division of Oncology) and the Laboratory Head for the Hitchins' Translational Epigenetics Lab at Stanford University. Her research focus is the genetic and epigenetic mechanisms (and their interactions) underlying human disease, mainly as applied to cancer predisposition and outcomes. Her PhD training at University College London, UK was in Clinical Genetics. She undertook post-doctoral training at Imperial College London and University College London, before taking up a Faculty position at The University of New South Wales in Sydney, Australia. She has published ~60 peer-reviewed papers, reviews and book chapters. Her seminal work on the role of epimutations in human cancer predisposition and their variable patterns of inheritance in cancer-affected families have been published in first-author papers in leading journals, including the New England Journal of Medicine, Nature Genetics, Cancer Cell, and Gastroenterology, with Opinion Perspectives published in Nature Reviews Cancer. She received widespread media coverage for the discovery of non-Mendelian and Mendelian transmission patterns of constitutional MLH1 epimutations. From 2008 until her departure in 2013, 100% of her salary was covered through prestigious nationally competitive fellowships acquired from government organizations. Dr Hitchins' research in the genetic and epigenetic causes of cancer risk and outcomes continues, with clinical observational studies as well as molecular pathological epidemiology studies in cancer patients.
Dr. Aboul-Enein, author and presenter for many professional articles, studies, and projects is currently working on several extensive writing projects related to healthcare reform and innovation. Dr. Aboul-Enein has been involved in research dealing in health access with feasibility analysis and healthcare economic issues related to the need to provide prevention as a cost saving mechanism. He served as a reservist officer in the U.S. Public Health Service Commissioned Corps with the rank of lieutenant commander involved as a nurse practitioner in correctional care and as a strategic health care advisor to the Office of the Surgeon General. Dr. Aboul-Enein has been an avid writer and faculty member about issues related to Population Health, Vulnerable Populations and need to empower Nurse Practitioners within large and small healthcare systems within urban and rural communities. Dr. Aboul-Enein’s passion towards healthcare reform is a result of the key issue that without Innovation, Risk taking and Empowerment- Healthcare Reform will be extremely difficult to implement.The Empowering Clinician through Population Health Model provides a means to developing Community Health Collaborative among local stakeholders, as all healthcare is local. As a healthcare speaker, writer, and consultant, Dr. Faisal Aboul-Enein has explored the future of healthcare with clients ranging from Universities, Community Health Centers, Physician Group Practices and Networks, Hospital System Networks, Clinician Groups, Healthcare Innovators and Entrepreneurs, and Investors of Critical Healthcare Ventures. At these universities, previously mentioned, his educational focuses include but are not limited to: the Graduate Programs in Nursing Management and Leaders, Healthcare Innovation, and Healthcare Administration, Masters in Health Administration
Dr. Aboul-Enein has a BSN (Magna Cum Laude) from University of Central Arkansas. He hold a Master in Public Health and a Master’s of Science in Nursing, specialization in Family Nurse Practitioner from the University of Texas Health Science Center at Houston. He holds Doctor of Public Health with a specialization in Community Health, Healthcare Administration from the University of Texas Health Science Center at Houston. He also is a Fellow of the Royal Society of Public Health and a Fellow of the American College of Healthcare Executives. He is fluent in Arabic, English and Spanish.
Jana Slobodnikova. M.D., end study on Charles University in Prague., gradued - CSc / PhD / completed at the age 38 years from Institus of Experimental Oncology Slovac Scientic Academy. Ass. Prof. in 43 years from Trnaviensis University, Prof. emeritus at age 45 years from St. Elizabeth High Scool. I have lectured at several universities - Prague, Tren?ín, Trnava and Bratislava. I am the author of teaching script, university textbooks, I lead workshops, I organize international congresses and worksops Her has published more than 90 scientific papers, from then 25 papers in renomed journals and has been serving as an 5 editorial board member of repute. Her has published 3 monography, Her founded the Section of Breast Imaging in 1996, from 1996 her is president The Section of Breast Imaging of Slovak radiologic Society and vice president The Slovak Society of Ultrasound in Medicine. Membership in organizations : ECR, EUSOBI, EFSUMB , SSUM ( Slovak Society of Ultrasound in Medicine ) and SRS ( Slovak Radiology Society).
Her has published more than 90 scientific papers, from then 25 papers in renomed journals and has been serving as an 5 editorial board member of repute. Her has published 3 monography, Her founded the Section of Breast Imaging in 1996, from 1996 her is president The Section of Breast Imaging of Slovak radiologic Society and vice president The Slovak Society of Ultrasound in Medicine. Membership in organizations : ECR, EUSOBI, EFSUMB , SSUM ( Slovak Society of Ultrasound in Medicine ) and SRS ( Slovak Radiology Society).
Dr. Nicolini graduated (summa cum laude) at School of Medicine, University of Pisa in 1974. He received postgraduate diplomas at University of Pisa in Internal Medicine (1980), Pneumology (1984), and Nuclear Medicine (1986). His research interests include breast and gastrointestinal cancer and their metastases, tumour markers, post-operative follow-up, physiopathology, immunology and immunotherapy of cancer, and thyroid tumours.
Since 1975 he has contributed to research in neuroendocrinology and thyroid physiopathology. Additionally, he has worked on a study aimed at distinguishing benign from malignant thyroid tumors by fine needle aspiration and biopsy (FNA, FNB). Later, this research has had further developments with studies on galectin. The achieved results have permitted to better select patients with malignant thyroid nodules who need surgery, hence reducing the number of undetected malignant cases. From 1978 to nowadays, Dr. Nicolini is the principal investigator of a clinical research aimed at defining the usefulness of serum tumor markers for early detection and treatment of distant metastases from breast and colorectal cancer. Methods and diagnostic accuracy of different serum tumor markers have been examined. The accuracy of instrumental examinations has been evaluated too. The scope of this research is to offer to patients a post-operative follow-up with high effectiveness/cost ratio. During last decade, his research has been mainly devoted to immunology: specifically, the evaluation of immunogical parameters (total lymphocytes and subsets, cytokines and growth factors) both in healthy subjects, and in breast cancer and in endocrine dependent metastatic breast cancer patients treated with hormone-immunotherapy. Based upon the results of this research, an interpretative model of the relationships between immune system and tumor cell biology has been proposed. The same model has also been applied to better comprehend the improved clinical outcome obtained in gastrointestinal cancer patients at high risk of relapse.
Dr. Sherry Bradford attended undergraduate school at SUNY at Buffalo and was awarded a full tuition scholarship to pursue her PhD graduate degree (Biochemistry) from the University of Buffalo/ Roswell Park Cancer Institute Division of SUNY at Buffalo School of Medical and Biomedical Sciences. During her clinical laboratory vocation, she was solicited by the Chief of Surgery at Millard Fillmore Hospital, Buffalo, NY, to direct the Surgical Research laboratory. There she successfully led the research on the use of human microvascular umbilical cord endothelium for lining stents. Besides her research, for the Chief of Staff, her responsibilities also included training ‘incoming” academic interns. It was while Sherry was at Millard Fillmore Hospital, that she was awarded the “1st Place - Award for Excellence in Research” from the American Federation for Clinical Research, and the “1st Place - Award for Excellence in Research” – SUNY at Buffalo, Roswell Park Cancer Institute Research Forum. In 1997, Dr. Bradford was approached by the Department of Pharmacokinetics, at Millard Fillmore Hospital, to lead their newly formed Pharmacokinetics Oncology Department. As the Principal Investigator, she was charged with the responsibility to develop an in vitro chemosensitivity test on tumor cells using the flow cytometer. In 2008, Dr Bradford and colleagues form AccuTheranostics and the idea od Oncology Personalized Medicine based on the specific patient’s own biochemical and genetic profile to administer personized treatment regimens. Currently, Dr. Bradford sits on the EDITORIAL BOARD of the International Journal of Medical and Health Sciences Research; on the EDITORIAL BOARD of Insights in Cancer Research, Editorial Board Member (Editor-in-Chief) for the Scientific Federation of Oncology & Cancer: Editorial Board Member of the Journal of Biomolecular Research and Therapy; and has authored and co-authored a number of scientific peer-reviewed manuscripts. She is also a member of many professional organizations including (but not limited to): International Metabolic Cancer Group, AACR, ASCO, and GLIFCA. She has been and will be an invited speaker at various domestic and international scientific meetings including: Invited Speaker: Proceedings of the 6th Int’l Conf on Frontiers of Polymers and Adv Materials, Recife, Brazil, March 2001; Key Note Speaker: Cancer Science 3rd World Congress Oct. 21, 2013 – San Francisco, CA; Plenary Speaker, Cancer Science 4th World Congress: Valencia, Spain, Sept. 1-3, 2015; International Expert and Key Note Speaker: INDO-GLOBAL HEALTHCARE SUMMIT & EXPO 2014, Hyderabad, India from July 23-26, 2015; Key Note Speaker: Dubai, United Arab Emirates, Aug 27-29, 2015; Keynote Speaker Gynecologic Oncology, May 19-21, 2016, San Antonio, Tx. This Year (2017) Keynote Speaker in Rome, Portugal, Dubai, Chicage, San Francisco and Philadelphia. Dr. Bradford also holds one patent: U.S. Patent No. 6485714, Published Patent - Serial No./Application No. 10/340,858, and 3 (2016) – patents pending (2016).
Breast Cancer Research